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A novel JK null allele associated with typing 
discrepancies among African Americans
K.L. Billingsley, J.B. Posadas, J.M. Moulds, and L.K. Gaur
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The Jknull (Jk-3) phenotype, attributable to null or silenced 
alleles, has predominantly been found in persons of Polynesian 
descent. With the increased use of molecular genotyping, many 
new silencing mutations have been identified in persons of other 
ethnic backgrounds. To date, only two JK null alleles have been 
reported in African Americans, JK*01N.04 and JK*01N.05. 
A comparative study was undertaken to determine whether 
JK mutations were present in the regional African American 
population. Results of donor genotyping were compared with 
previously recorded results of serologic tests, and discrepant 
results were investigated. Although the two previously identified 
polymorphisms were not detected in the discrepant samples, a 
novel allele (191G>A) was identified and was assigned the ISBT 
number JK*02N.09. This study illustrates a limitation of using 
single-nucleotide polymorphisms for prediction of blood group 
antigens. Immunohematology 2013;29:145–148.
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The Kidd blood group system was first described in 1951 
when anti-Jka was found to cause hemolytic disease of the 
fetus and newborn (HDFN).1 Anti-Jkb was reported in 1953, 
also as a case of HDFN,2 and in 1959, anti-Jk3 was described 
in a posttransfusion patient whose red blood cells (RBCs) 
typed Jk(a–b–).3 Since this time, many examples of anti-Jka 
and anti-Jkb have been reported. Owing to the rapid decrease 
in antibody titer, these clinically significant antibodies can be 
difficult to detect and are frequently associated with severe 
delayed hemolytic transfusion reactions. In fact, fatal delayed 
hemolytic transfusion reactions caused by anti-Jka and anti-
Jkb remain among those most reported to the U.S. Food and 
Drug Administration.4
The Kidd glycoprotein is found on RBCs as well as on 
endothelial cells of the vasa recta, the vascular supply of the 
renal medulla. It is an integral protein of the RBC, spanning 
the membrane ten times. The glycoprotein functions as a 
urea transporter for the cells and helps maintain osmotic 
stability. Individuals lacking the glycoprotein are known to 
have decreased urine concentrating ability, but they have no 
known disease associations or RBC abnormalities. The Kidd 
glycoprotein consists of 389 amino acids and is encoded by 
the SLC14A1 gene located on chromosome 18. Eleven exons 
are distributed across 30 kb of DNA. As exons 1 through 3 
are not translated, the mature protein is encoded by exons 4 
through 11.5 The SLC14A1 gene has two major codominant 
alleles, JK*A (JK*01) and JK*B (JK*02), which result from a 
single-nucleotide polymorphism (SNP), 838A>G (rs1058396).
To date, 14 polymorphisms causing JKnull phenotypes 
have been reported: 6 on the JK*A allele and 8 on the JK*B 
allele (Table 1). Of the known polymorphisms, only two 
have been associated with individuals of African American 
ethnicity (JK*01N.04 and JK*01N.05).6,7 Investigation into 
samples whose genotype results for JK*A and JK*B differed 
from results previously obtained with serologic testing led to 
the identification of an additional mutation that resulted in the 
lack of expression of the JK protein.9
Materials and Methods
Sample Selection
After informed consent was obtained, whole-blood 
samples from African American blood donors and patients 
from the tristate service area (Louisiana, Texas, and Arkansas) 
were obtained for testing. Genomic DNA was extracted and 
prepared using either a manual or an automated method 
(Gentra PureGene or QIAcube, Qiagen, Valencia, CA).
Serologic Studies
All of the discrepant donor samples were tested either on 
multiple donations or, if confirmation testing was performed 
on the same sample, with multiple antisera. Of the three 
donors with genotype or phenotype discrepancies, donor 
one was tested on two different donations using a polyclonal 
reagent (Anti-Jkb, Immucor, Norcross, GA). Donor two was 
tested twice on the same donation: once with a polyclonal 
reagent (anti-Jkb, Immucor) and once with an in-house human 
source of anti-Jkb. Finally, donor three was tested twice, first 
with a polyclonal serum (anti-Jkb Immucor) and then with a 
monoclonal reagent (Anti-Jkb, Ortho Clinical Diagnostics, 
Raritan, NJ). No weakened expression was observed with 
any of the antisera; in fact, all serologic results were negative. 
As for the patient, because his discrepancy was discovered 
on a retrospective genotype and phenotype comparison of 
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results from 250 patients with sickle cell disease, testing was 
not confirmed by additional serology. The patient’s complete 
phenotype was performed as part of the immunohematology 
reference laboratory (IRL) serologic workup that led to the 
identification of alloanti-Jkb.
Molecular Assays
RBC blood group genotyping was performed using a 
microarray kit (HEA BeadChip assay version 1.2, BioArray 
Solutions, LLC, Warren, NJ) according to the manufacturer’s 
directions. This microarray detects the 838G>A polymorphism 
corresponding to JK*A or JK*B, as well as 23 additional 
polymorphisms associated with 34 RBC antigens. Genotype 
results were compared with previous serologic typing results 
for concordance. For samples with discordant results, the 
genotype was confirmed using another kit (Red Cell EZ Type 
KDK assay, GTI Diagnostics, Milwaukee, WI), according to the 
manufacturer’s directions. Samples that remained discordant 
were sent to Puget Sound Blood Center for DNA sequencing. 
The coding regions of the JK genes (exons 4–10) along with 
the promoter region6 were enzymatically amplified in a total 
volume of 50 µL with 100 ng of DNA, 1.25 units of  polymerase 
(Taq, 1× Green GoTaq Flexi Buffer, Promega, Madison, WI), 
1.5 mM MgCl2, 0.125 mM deoxyribonucleoside diphosphate, 
and 100 ng each forward and reverse primer. Polymerase chain 
reaction conditions included denaturation for 2 minutes at 
95°C, followed by 35 cycles of 95°C for 30 seconds, 55°C for 30 
seconds, and 72°C for 1 minute, and then a final elongation for 
5 minutes at 72°C. Polymerase chain reaction products were 
purified with a kit (QIAquick PCR purification kit, Qiagen) and 
sequenced on an automated system (ABI Prism 3100 Applied 
Biosystems, Foster City, CA). The amplified products were 
sequenced (ABI Prism 3100 Applied Biosystems), they were 
aligned to the reference JK allele, and the electropherograms 
were scanned for SNPs. The sequences were aligned in FASTA 
format using a software program (BLAST, http://blast.ncbi.
nlm.nih.gov/).
Results
Data were collected from January 1, 2009, through 
September 30, 2010. Identified during the 21-month study 
period were 1079 genotyped donors who had been previously 
typed for Jka and 1235 genotyped donors who had been 
previously typed for Jkb by serologic methods. On comparison 
of serologic results with molecular typing results, three 
samples were found to be discordant. All three were 
heterozygous for the 838G>A SNP and were predicted to be 
Jk(a+b+); however, the samples typed Jk(b–) by serologic 
methods.
DNA sequencing of the three samples indicated that all 
had wild-type promoter regions and confirmed heterozygosity 
at 838G>A. However, a 191G>A (R64Q) polymorphism 
was also present in the heterozygous state (Fig. 1). Given 
the serologic phenotype in the three donors, it is most likely 
that the 191G>A polymorphism is carried on the JK*B 
allele. Further, this missense SNP is proposed to result in 
no or undetectable levels of Jkb on the RBC surface. Further 
Table 1. International Society for Blood Transfusion terminology for Kidd blood group alleles*
Phenotype Allele name Nucleotide change Intron/exon Amino acid change Reference number
JK:–3 or Jk(a–b–) JK*01N.01 Exons 4 and 5 deleted 4 and 5 Initiation Met absent
JK:–3 or Jk(a–b–) JK*01N.02 202C>T 5 Gln68Stop
JK:–3 or Jk(a–b–) JK*01N.03 582C>G 7 Tyr194Stop
JK:–3 or Jk(a–b–) JK*01N.04 956C>T 10 Thr319Met 6
JK:–3 or Jk(a–b–) JK*01N.05 561C>A 7 Tyr187Stop 7
JK:–3 or Jk(a–b–) JK*01N.06 IVS5–1g>a Intron 5 Exon 6 skipped; in frame
JK:–3 or Jk(a–b–) JK*02N.01 IVS5–1g>a Intron 5 Exon 6 skipped; in frame 8
JK:–3 or Jk(a–b–) JK*02N.02 IVS5–1g>c Intron 5 Exon 6 skipped; in frame
JK:–3 or Jk(a–b–) JK*02N.03 222C>A 5 Asn74Lys
JK:–3 or Jk(a–b–) JK*02N.04 IVS7+1g>t Intron 7 Exon 7 skipped; frameshift➞Leu223Stop
JK:–3 or Jk(a–b–) JK*02N.05 723delA 8 Frameshift➞Ile262Stop
JK:–3 or Jk(a–b–) JK*02N.06 871T>C 9 Ser291Pro 8
JK:–3 or Jk(a–b–) JK*02N.07 896G>A 9 Gly299Glu
JK:–3 or Jk(a–b–) JK*02N.08 956C>T 10 Thr319Met
JK:–3 or Jk(a–b–) JK*02N.09 191G>A 4 Arg64Gln 9, this study
*Reference allele JK*02 encodes JK2, JK3. Source: http://www.isbtweb.org/working-parties/red-cell-immunogenetics-and-blood-group-terminology/blood-
group-terminology/.
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investigation, including cDNA analysis and protein modeling, 
would be necessary to demonstrate these interpretations. The 
allele has been assigned the ISBT name JK*02N.09. 
A retrospective review of patient testing also yielded a 
discrepancy between serology and molecular typing. Of the 
250 patient records reviewed, one patient genotyped JK*A/
JK*B, but phenotyped Jk(b–) and had produced an alloanti-
Jkb. The DNA sample was sequenced, and the patient was 
confirmed to carry the 191G>A substitution.
This previously unpublished SNP has thus far only been 
detected in Asians (Gaur LK, unpublished data) using a primer 
set JK-E3-FP1: 5′ACAGCCCCACTATGGTTAGA3′ and JK-
E4-RP1: 5′CTGGCTGAGCAAGAGGGC3′ that encompasses 
codons 10 to 111 (872 bp); so this is the first report of this 
polymorphism in African Americans. 
Discussion
Although no longer in its infancy, the role of molecular 
technologies in the blood bank environment continues 
to evolve. With the advent of high-throughput molecular 
assays that are often more economical and efficient than 
routine serology, donor screening has been revolutionized.10 
Although some microarray assays have incorporated JK null 
allele detection (IDCore+, Progenika, Derio, Spain), these are 
usually limited to the more common Polynesian and Finnish 
alleles, JK*02N.01 and JK*02N.06, respectively.9 Two JK nulls 
(JK*01N.04 and JK*01N.05) have previously been found in 
African Americans, but their occurrence is rare.6,7 However, 
this new allele, JK*02N.09, occurred in 1 of 412 donors tested. 
As shown by this study, antigen screening that uses only SNP 
analysis may not detect blood group mutations caused by 
silencing mutations and may lead to erroneous testing results. 
Of note, this method of donor screening will not increase 
the risk to alloimmunized patients, as a unit would appear 
to be positive for the antigen and, therefore, not selected for 
transfusion to a patient with a known antibody. However, 
there is a risk of mistyping patients, and if a patient’s genotype 
will be used for prophylactic antigen matching, as in the case 
of sickle cell disease or warm autoimmune hemolytic anemia, 
limitations of molecular assays must be considered.
Given the prevalence of the 191G>A SNP in the study 
population, a comparison of previously typed patients with 
sickle cell disease was conducted, and indeed the new JK 
allele was detected in one patient who had produced alloanti-
Jkb. This knowledge has led to a change in LifeShare Blood 
Centers protocol, such that any African American patient who 
genotypes as JK*A/JK*B will have the phenotype confirmed 
by serology whenever possible.
African Americans are known to have silencing mutations 
in other blood group genes, e.g., FY and GYPB, and detection of 
these has been incorporated into existing microarrays. Perhaps 
as molecular assays continue to evolve, detection of additional 
mutations leading to JK nulls will be incorporated as well. 
More data as to the frequency of the 191G>A polymorphism 
in African Americans in other geographic locations may be of 
interest. Additionally, given that anti-Jka and anti-Jkb can be 
weakly reactive as well as show a dosage effect, those donors 
used for reagent RBC panels should be confirmed as truly 
homozygous for the JK*A or JK*B gene. As with many other 
blood group systems, what once appeared to be a simple blood 
group system with two common antigens and one rare null 
type has increasingly become more complex.
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Fig. 1 Electropherogram of the DNA sequence for exon 4 of the JK 
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